ClinicalTrials.gg
CompletedNCT01401985Updated May 22, 2026

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

A Phase 2 interventional study of TD-1211 and Placebo in Opioid Induced Constipation, sponsored by Glycyx Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Glycyx Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies in Opioid-Induced Constipation with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Opioid-Induced Constipation · United States.

Enrollment
27th of 40
95 · median 227
Started
2011
with 9 others
Phase 2
12 of 43
none open now
Registered
30th of 43
by date
Lead sponsor
6 of 43
Glycyx Therapeutics

Among the 43 studies in Opioid-Induced Constipation with a site in United States, this one is the 27th largest by enrollment of the 40 interventional ones that give a count, is one of 10 that started in 2011, is one of 12 in phase 2, and was the 30th registered.

Opioid-Induced Constipation

87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.

Browse Opioid-Induced Constipation studies →

Open to participants now

1 of the 43 studies in Opioid-Induced Constipation with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Opioid-Induced Constipation studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Opioid-Induced Constipation with a site in United States, or all of them as a file.
02

Study summary

A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation

03

Conditions studied

  • Opioid Induced Constipation

Keywords

  • Opioid induced constipation
  • OIC
  • Constipation
  • Opioid side effects
  • morphine induced constipation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • stable dose of opioids for at least 12 weeks before screening visit
  • less than or equal to 5 spontaneous bowel movements for a 2 week period and experiencing at least one other symptom of constipation
  • willing to stop laxatives and other bowel treatments; rescue laxative allowed

Exclusion criteria

Exclusion Criteria:

  • condition or illness (other than the condition for which the pain medication was prescribed)
  • Have participated in another clinical trial of an drug 30 days prior to screening
  • History of cancer treatment except adequately treated localized skin cancer within 5 years of screening
  • History of chronic constipation prior to opioid therapy
  • Females who are pregnant or breast feeding
  • Have any condition that may affect drug absorption (e.g. previous GI surgery)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Cohort 1

    5 mg TD-1211 once daily for 4 days followed by 10 mg for 14 days

    Drug: TD-1211

  • Experimental
    Cohort 2

    5 mg TD-1211 once daily for 4 days followed by 15 mg for 14 days

    Drug: TD-1211

  • Experimental
    Cohort 3

    5 mg TD-1211 once daily for 2 days followed by 10 mg for 14 days

    Drug: TD-1211

  • Experimental
    Cohort 4

    5 mg TD-1211 once daily for 2 days followed by 15 mg for 14 days

    Drug: TD-1211

  • Experimental
    Cohort 5

    2 mg TD-1211 once daily for 14 days

    Drug: TD-1211 · Drug: Placebo

  • Experimental
    Cohort 6

    2.5 mg TD-1211 every 6 hours for 14 days

    Drug: TD-1211 · Drug: Placebo

Interventions

  • Capsules

  • DrugPlacebo

    Capsules

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of TD-1211

    Time frame: 14 days

Secondary outcomes

  1. Complete spontaneous bowel movements (CSBM); Spontaneous bowel movements (SBM)

    Change from baseline in the weekly SBM and CSBM frequency

    Time frame: Weekly assessments throughout Treatment Period

07

Study locations

1 site
  • Theravance Biopharma Investigational Site
    Pasadena, California 91105, United States
08

References and documents

Individual participant data

Plan to share: No — Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of May 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2011
First posted
Jul 26, 2011
Start
Oct 2011
Primary completionActual
May 2012
CompletionActual
Aug 2012
Results delay requested
Jun 5, 2013
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01401985
Lead sponsor
Glycyx Therapeutics
Responsible party
Sponsor
First posted
Jul 26, 2011
Start date
Oct 2011
Primary completion
May 2012
Completion
Aug 2012
Last update
May 22, 2026

Study contacts

Medical Monitor
study director · Theravance Biopharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axelopran

Start the discussion